Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China - Takeaways - MDSpire

Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China

  • By

  • Weikai Wang

  • Zhe Lv

  • Haitong Wu

  • Hua Zhang

  • Zhen Chen

  • Yong Zhou

  • Zhangyan Guo

  • Jingmei Li

  • Le Ma

  • Dan Yao

  • Ying Wang

  • Ru Lin

  • Yajun Niu

  • Yuhao Ma

  • Xinxin Yan

  • Shan Jia

  • Taining Zhang

  • Yufei Wang

  • Yanqiang Du

  • Yi Wang

  • July 14, 2026

Share

  • 1

    Accidental injury is a leading cause of mortality in pediatric patients, often requiring ECMO support due to severe trauma.

  • 2

    This study compares nafamostat mesilate and unfractionated heparin for anticoagulation in pediatric trauma patients on ECMO.

  • 3

    Forty patients were divided into two groups: 24 received nafamostat mesilate and 16 received unfractionated heparin.

  • 4

    The UFH group had a higher incidence of new-onset active bleeding and circuit thrombosis compared to the nafamostat mesilate group.

  • 5

    Nafamostat mesilate provides effective anticoagulation with a significantly lower risk of bleeding than unfractionated heparin.

Original Source(s)

Related Content